Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy

Takahisa Eriguchi, Atsunori Yorozu, Nobuko Kuroiwa, Yasuto Yagi, Toru Nishiyama, Shiro Saito, Kazuhito Toya, Takashi Hanada, Yutaka Shiraishi, Toshio Ohashi, Naoyuki Shigematsu

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: We examined the factors associated with urinary toxicities because of brachytherapy with iodine-125 with or without supplemental external beam radiotherapy (EBRT) for prostate cancer. Methods and Materials: We investigated 1313 patients with localized prostate cancer treated with iodine-125 brachytherapy with or without supplemental EBRT between 2003 and 2009. The International Prostate Symptom Score (IPSS) and Common Terminology Criteria for Adverse Events data were prospectively determined. Patients, treatment, and implant factors were investigated for their association with urinary toxicity or symptoms. Results: IPSS resolution was not associated with biologically effective dose (BED). Baseline IPSS, total needles, and the minimal dose received by 30% of the urethra had the greatest effect according to multivariate analysis (MVA). Urinary symptom flare was associated with baseline IPSS, age, BED, and EBRT on MVA. Urinary symptom flare and urinary Grade 2 or higher (G2+) toxicity occurred in 51%, 58%, and 67% (p = 0.025) and 16%, 22%, and 20% (p = 0.497) of the 220 Gy BED groups, respectively. Urinary G2+ toxicity was associated with baseline IPSS, neoadjuvant androgen deprivation therapy (NADT), and seed density on MVA. When we divided patients into four groups according to prostate volume (

Original languageEnglish
JournalBrachytherapy
DOIs
Publication statusAccepted/In press - 2015 Oct 29

Fingerprint

Brachytherapy
Iodine
Prostate
Radiotherapy
Multivariate Analysis
Prostatic Neoplasms
Urethra
Terminology
Androgens
Needles
Seeds
Therapeutics

Keywords

  • I
  • Brachytherapy
  • Higher biological effective dose
  • Neoadjuvant androgen deprivation therapy
  • Prostate cancer
  • Supplemental external beam radiotherapy
  • Urinary toxicity

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy. / Eriguchi, Takahisa; Yorozu, Atsunori; Kuroiwa, Nobuko; Yagi, Yasuto; Nishiyama, Toru; Saito, Shiro; Toya, Kazuhito; Hanada, Takashi; Shiraishi, Yutaka; Ohashi, Toshio; Shigematsu, Naoyuki.

In: Brachytherapy, 29.10.2015.

Research output: Contribution to journalArticle

@article{7b13ac10868548bf97cf0a1c9e1dba00,
title = "Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy",
abstract = "Purpose: We examined the factors associated with urinary toxicities because of brachytherapy with iodine-125 with or without supplemental external beam radiotherapy (EBRT) for prostate cancer. Methods and Materials: We investigated 1313 patients with localized prostate cancer treated with iodine-125 brachytherapy with or without supplemental EBRT between 2003 and 2009. The International Prostate Symptom Score (IPSS) and Common Terminology Criteria for Adverse Events data were prospectively determined. Patients, treatment, and implant factors were investigated for their association with urinary toxicity or symptoms. Results: IPSS resolution was not associated with biologically effective dose (BED). Baseline IPSS, total needles, and the minimal dose received by 30{\%} of the urethra had the greatest effect according to multivariate analysis (MVA). Urinary symptom flare was associated with baseline IPSS, age, BED, and EBRT on MVA. Urinary symptom flare and urinary Grade 2 or higher (G2+) toxicity occurred in 51{\%}, 58{\%}, and 67{\%} (p = 0.025) and 16{\%}, 22{\%}, and 20{\%} (p = 0.497) of the 220 Gy BED groups, respectively. Urinary G2+ toxicity was associated with baseline IPSS, neoadjuvant androgen deprivation therapy (NADT), and seed density on MVA. When we divided patients into four groups according to prostate volume (",
keywords = "I, Brachytherapy, Higher biological effective dose, Neoadjuvant androgen deprivation therapy, Prostate cancer, Supplemental external beam radiotherapy, Urinary toxicity",
author = "Takahisa Eriguchi and Atsunori Yorozu and Nobuko Kuroiwa and Yasuto Yagi and Toru Nishiyama and Shiro Saito and Kazuhito Toya and Takashi Hanada and Yutaka Shiraishi and Toshio Ohashi and Naoyuki Shigematsu",
year = "2015",
month = "10",
day = "29",
doi = "10.1016/j.brachy.2015.12.011",
language = "English",
journal = "Brachytherapy",
issn = "1538-4721",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy

AU - Eriguchi, Takahisa

AU - Yorozu, Atsunori

AU - Kuroiwa, Nobuko

AU - Yagi, Yasuto

AU - Nishiyama, Toru

AU - Saito, Shiro

AU - Toya, Kazuhito

AU - Hanada, Takashi

AU - Shiraishi, Yutaka

AU - Ohashi, Toshio

AU - Shigematsu, Naoyuki

PY - 2015/10/29

Y1 - 2015/10/29

N2 - Purpose: We examined the factors associated with urinary toxicities because of brachytherapy with iodine-125 with or without supplemental external beam radiotherapy (EBRT) for prostate cancer. Methods and Materials: We investigated 1313 patients with localized prostate cancer treated with iodine-125 brachytherapy with or without supplemental EBRT between 2003 and 2009. The International Prostate Symptom Score (IPSS) and Common Terminology Criteria for Adverse Events data were prospectively determined. Patients, treatment, and implant factors were investigated for their association with urinary toxicity or symptoms. Results: IPSS resolution was not associated with biologically effective dose (BED). Baseline IPSS, total needles, and the minimal dose received by 30% of the urethra had the greatest effect according to multivariate analysis (MVA). Urinary symptom flare was associated with baseline IPSS, age, BED, and EBRT on MVA. Urinary symptom flare and urinary Grade 2 or higher (G2+) toxicity occurred in 51%, 58%, and 67% (p = 0.025) and 16%, 22%, and 20% (p = 0.497) of the 220 Gy BED groups, respectively. Urinary G2+ toxicity was associated with baseline IPSS, neoadjuvant androgen deprivation therapy (NADT), and seed density on MVA. When we divided patients into four groups according to prostate volume (

AB - Purpose: We examined the factors associated with urinary toxicities because of brachytherapy with iodine-125 with or without supplemental external beam radiotherapy (EBRT) for prostate cancer. Methods and Materials: We investigated 1313 patients with localized prostate cancer treated with iodine-125 brachytherapy with or without supplemental EBRT between 2003 and 2009. The International Prostate Symptom Score (IPSS) and Common Terminology Criteria for Adverse Events data were prospectively determined. Patients, treatment, and implant factors were investigated for their association with urinary toxicity or symptoms. Results: IPSS resolution was not associated with biologically effective dose (BED). Baseline IPSS, total needles, and the minimal dose received by 30% of the urethra had the greatest effect according to multivariate analysis (MVA). Urinary symptom flare was associated with baseline IPSS, age, BED, and EBRT on MVA. Urinary symptom flare and urinary Grade 2 or higher (G2+) toxicity occurred in 51%, 58%, and 67% (p = 0.025) and 16%, 22%, and 20% (p = 0.497) of the 220 Gy BED groups, respectively. Urinary G2+ toxicity was associated with baseline IPSS, neoadjuvant androgen deprivation therapy (NADT), and seed density on MVA. When we divided patients into four groups according to prostate volume (

KW - I

KW - Brachytherapy

KW - Higher biological effective dose

KW - Neoadjuvant androgen deprivation therapy

KW - Prostate cancer

KW - Supplemental external beam radiotherapy

KW - Urinary toxicity

UR - http://www.scopus.com/inward/record.url?scp=84975690632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975690632&partnerID=8YFLogxK

U2 - 10.1016/j.brachy.2015.12.011

DO - 10.1016/j.brachy.2015.12.011

M3 - Article

C2 - 26924022

AN - SCOPUS:84975690632

JO - Brachytherapy

JF - Brachytherapy

SN - 1538-4721

ER -